Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Therapy Shows Promise for Peanut Allergy

Published: Friday, January 25, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Results appeared in the January 2013 issue of the Journal of Allergy and Clinical Immunology.

A liquid therapy placed underneath the tongues of people with peanut allergy can reduce their sensitivity to peanuts, a new study found.

With further development, the experimental technique could make life easier for people whose only current option is to avoid everything that contains peanuts.

Food allergy comes about when the immune system responds to a harmless food as if it were a threat.

Symptoms can range from hives and itching to a life-threatening condition called anaphylaxis, which can involve throat swelling, a sudden drop in blood pressure, trouble breathing, fainting and dizziness.

In both children and adults, peanuts are one of the most common foods to cause allergic reactions. About 3 out of every 500 people in the United States are allergic to peanuts.

The only way to prevent the symptoms of food allergy is to avoid the food altogether. But it’s difficult to completely avoid exposure to peanuts and all the products made with them.

Recent studies have found that oral immunotherapy may hold promise for treating food allergy. A research team led by Dr. David M. Fleischer of National Jewish Health in Denver and Dr. A. Wesley Burks at the University of North Carolina set out to test whether an approach called sublingual immunotherapy could be used to treat peanut allergy.

The medically supervised therapy involves placing a small amount of the allergy-causing substance (allergen) under the tongue to decrease the body’s sensitivity to the allergen.

The scientists enrolled 40 people, ages 12 to 37 years, with peanut allergy. All were on a peanut-free diet. After an initial food challenge to measure how much peanut powder they could eat without having an allergic reaction, participants were randomly assigned to receive sublingual immunotherapy or placebo.

The therapy group received escalating doses of peanut powder every 2 weeks until a maintenance dose was reached.

The trial was funded by NIH's National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) and National Center for Advancing Translational Sciences (NCATS).

The researchers found that 14 of the 20 participants (70%) given peanut immunotherapy were able to consume at least 10 times more peanut powder after 44 weeks of daily therapy than they could at the beginning of the study.

In contrast, only 3 of the 20 participants (15%) given placebo could safely consume such an increase.

After 68 weeks, those on immunotherapy could consume significantly more peanut powder without having an allergic reaction than those given placebo. The therapy caused only minor side effects, such as itching in the mouth.

With more work, the scientists hope that sublingual immunotherapy could protect people from unintentional exposure to peanuts.

“These results are encouraging,” Burks says. “The immune response was stronger than we thought it might be, and the side effects of this treatment were relatively small. However, the magnitude of the therapeutic effect was somewhat less than we had anticipated. That's an issue we plan to address in future studies.”

This is one of several federally funded trials currently testing immune-based approaches to food allergy.

The researchers caution that people should not try any of these techniques on their own because they carry a significant risk for allergic reactions. These therapies should be administered only under the guidance of trained clinicians.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Tuesday, August 23, 2016
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Friday, August 12, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Wednesday, July 27, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Wednesday, May 18, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Scientific News
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Pinpointing Key Influenza-Fighting Immune Trigger
Immunologists have identified the protein trigger that recognises influenza virus infection in cells and triggers their death.
Sweet Spot of Human Immune System
Scientists propose answer to how the human immune system scales its response in proportion to threat to make it 'just right'.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Characterizing the Mouse Gut Microbiome
Study establishes the first public collection of bacteria from the intestine of mice.
Microchip Tech Improves Nanomaterial Safety Screening
Platform developed at UCLA uses lab-on-a-chip technology to predict how hazardous engineered nanomaterials might be.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!